Pasi Janne, MD, PhD on targeted therapy for lung cancer / Dana-Farber Cancer Insitute
1,566 views · Published 3 June 2013 · 1:43 · Indexed 30 October 2026
Channel: Dana-Farber Cancer Institute · 2013 · Science & Technology
Thousands of patients with an advanced form of lung cancer that carries a specific dysfunctional gene (ALK) are likely to fare better if treated with the targeted therapy (crizotinib) than with traditional chemotherapy, report Dana-Farber Cancer Institute researchers and a team of international collaborators.
More from this channel
-
0:18
Importance of Joining the Stem Cell Registry | Dana-Farber Cancer Institute
-
0:20
How to Join the Stem Cell Registry | Dana-Farber Cancer Institute
-
0:18
How to Register as a Stem Cell Donor | Dana-Farber Cancer Institute
-
3:03
Sportscaster Jim Britt for the Jimmy Fund | Dana-Farber Cancer Institute
-
0:07
Dana-Farber Banners | Dana-Farber Cancer Institute
-
2:08
Barbers for the Jimmy Fund | Dana-Farber Cancer Institute
-
1:43
Pets | Dana-Farber Cancer Institute
-
1:34
Healthy Eating for the Holiday Season | Dana-Farber Cancer Institute